WLNS [edited]<http://wlns.com/2017/08/04/warning-childrens-medicine-from-india-tests-positive-for-lead/>The Michigan Department of Health and Human Services issued a warning for parents on [Thu 3 Aug 2017] about an ayurvedic remedy called Balguti Kesaria. Recent testing of the product returned positive for elevated lead levels. Up to 2 children [FDA, see below, says 2. - Mod.SH] in south east Michigan, who were given the supplement, also tested positive for elevated lead levels.Balguti Kesaria is ground up and given to infants to promote proper digestion, improve the immune system, and to suppress coughing, colds, and high fevers.Family members told health officials they received the supplement from relatives in India. The same product can be purchased online and shipped to the United States. If you or your family have been using Balguti Kesaria discontinue use immediately, and have your blood tested for lead through your primary care provider.[by Mariah Harrison]--communicated by:ProMED-mail<promed@promedmail.org>******[2]Date: Fri 4 Aug 2017Source: FDA [edited]<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm570257.htm>The US Food and Drug Administration [FDA] is warning parents and caregivers not to use ""Balguti Kesaria (or Kesaria Balguti) Ayurvedic Medicine"" due to the risk of lead poisoning.FDA has not reviewed this product for safety or effectiveness. Exposure to lead can cause serious damage to the central nervous system, the kidneys and the immune system. In children, chronic exposure to lead -- even at low levels -- is associated with impaired cognitive function, including reduced IQ, behavioral difficulties, and other problems.This product is sold online and manufactured by multiple companies, including Kesari Ayurvedic Pharmacy in India. Individuals have also mailed or brought the product into the United States. ""Balguti Kesaria Ayurvedic Medicine"" is used with infants and children for a variety of conditions including rickets, cough and cold, worms and dentition (teething).FDA initially learned of this risk from the North Carolina Division of Public Health after the product was tested and found to contain high levels of lead. FDA was also notified by the Michigan Department of Health and Human Services of high levels of lead in 2 children who were given this product. Michigan's testing also found high levels of lead in the product. To date, FDA has received one adverse event report of high levels of lead and developmental delays in a child who was given this product.Anyone who is using this product or giving it to a child should stop immediately and consult a health care professional.Health care professionals and consumers are encouraged to report any adverse events potentially related to ""Balguti Kesaria Ayurvedic Medicine ""or any other alternative medicines to FDA's MedWatch Adverse Event Reporting Program: - complete and submit the report online: <www.fda.gov/MedWatch/report> - <download form> or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.--communicated by:ProMED-mail<promed@promedmail.org>[Michigan has been plagued with lead in the last year or so. First, the water, and now a complementary medicine product.As stated by the FDA article exposure to lead can cause serious damage to the central nervous system, the kidneys and the immune system. In children, chronic exposure to lead is associated with impaired cognitive function, and behavioral difficulties. Younger children may be more susceptible to the effects of lead, as US CDC has lowered its limits for children up to the age of 5 years.A blood test is necessary to determine the amount of lead in the blood. Chelation treatment is available for lead poisoning.For more information regarding symptoms of lead poisoning readers are referred to the moderator comments on ProMED-mail posting: Lead poisoning - USA (NC) 20161228.4729158. - Mod.TGA HealthMap/ProMED-mail map can be accessed at: <http://healthmap.org/promed/p/225>.]
